A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE

Glackin, Carlotta, Ph.D. Laboratory

Laboratory of Carlotta Glackin, Ph.D.
Dr. Glackin’s laboratory focuses on understanding the molecular mechanisms of normal human mesenchymal stem cell differentiation, and how key molecules in this process play a role in promoting tumor metastasis. This knowledge will provide valuable targets in developing novel cancer therapies. Additionally, Dr. Glackin is investigating how the unique properties of another type of human stem cell, the neural stem cell, may be exploited to deliver specifically targeted therapy for aggressive metastatic cancers. The following is a brief overview of these two major research areas:
 
MSCs and Metastases: A New “Twist” in Breast Cancer
Mesenchymal stem cells (MSCs) are multipotent stem cells, i.e. they can differentiate into several types of mature cells – most notably, bone, muscle and fat. Twist is an HLH (helix-loop-helix) protein abundant in MSCs that helps promote these normal differentiation pathways. Dr. Glackin’s research group has found that over-expression of Twist protein is present in metastatic breast cancer, particularly in bone metastases. This suggests that normal expression of Twist correlates with normal osteogenesis, but aberrant expression of Twist leads to bone metastases. By deciphering the molecular underpinnings of this aberrant expression (in particular, a process known as EMT), the group is developing innovative therapeutic interventions, such as STIs (soluble Twist inhibitors), in order to reduce the morbidity and mortality associated with highly aggressive metastatic cancers. 
 
Neural Stem Cells as Targeted Drug Delivery Vehicles
Human neural stem cells (NSCs) display inherent tumor-specific tropism in vivo and therapeutically engineered NSCs reduced tumor burden in animal models. Dr. Glackin’s lab has demonstrated that NSCs migrate towards breast cancer cells and specifically target breast tumors in vivo. Utilizing these proven inherent migratory and tumor targeting abilities, Glackin proposes to use genetically-engineered NSCs as a delivery vehicle for several types of drugs to treat metastatic breast cancer.
 
Lab Members:
 
Raquel Raices, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673)
rraices@coh.org
 
Christine Gjerdrum, B.Sc.
Graduate Student
626-256-HOPE (4673)
cgjerdrum@coh.org
 
Joyce Ho, B.A.
Graduate Student
626-256-HOPE (4673)
joycelho@gmail.com
 
Shan Li, M.Sc.
Graduate Student
626-256-HOPE (4673)
shali@coh.org
 
Anna Munoz, B.S.
Graduate Student
626-256-HOPE (4673)
anmunoz@coh.org
 
Jackie Andrews
Senior Secretary
626-256-HOPE (4673)
jandrews@coh.org
 

Research

MSCs and Twist
 
Understanding the Role of Twist in MSC Lineage Commitment
We are interested in the roles of Twist (and other HLH proteins) in maintaining uncommitted progenitor populations and their interactions with targets and signaling pathways which promote their differentiation into mesenchymal lineages. Our collaborators, Stan Gronthos (IMVS), Karen Lyons (UCLA), Sandra Sharp (CSULA) and I are currently investigating these processes in order to gain insights that will enable us to develop therapies to regulate human stem cell growth and development for the efficient repair of skeletal tissues. The use of human stem cells – whether derived from a variety of adult tissues or from human embryonic cells – is of paramount importance to this research. Two CSULA Master’s students, Anna Munoz and Joyce Ho, supported by City of Hope’s Cancer Collaborative Program, are initiating these studies. They have successfully cloned the Twist, Id-1 and Id-2 promoters into pGL4-luciferase, and are currently examining the differentiation of three MSC lineages (muscle, bone and fat) over time to determine the functional activity of Twist and Id-1 and Id-2 in this process. Their results will be combined with real-time PCR and immunohistochemical biomarker expression studies completed last year.
 
Twist in Breast Cancer Metastasis
In the past few years, our research group has also found Twist to be at higher levels in breast cancer cells when compared to normal breast tissues. Furthermore, over-expression of Twist is associated with highly metastatic disease. But what is the mechanism responsible here? The laboratory is currently conducting a series of experiments to understand how signaling pathways are affected by Twist over-expression in breast epithelial cells.
 
A pivotal event is a process known as EMT (epithelial-mesenchymal transition). Certain epithelial-associated proteins, such as E-cadherin (the “E” means “epithelial”) and keratin, are considered crucial to cell-cell adhesion. When they predominate, the cells “stick together”, and the motility required for wayward cells to break free and become invasive is hindered. In EMT, however, expression of E-cadherin and keratin is repressed, while expression of mesenchymal-associated proteins, most notably N-cadherin (“N” means “neural”) and vimentin, is activated. This decreases cell-cell adhesion, increases motility/invasiveness, and so promotes metastasis. We demonstrated that Twist directly regulates this transition. In fact, we and other groups have convincing evidence that Twist is required for breast tumor cell invasion.
 
Detailed Mechanistic Investigations of Twist-Mediated Metastasis
Graduate student Shan Li is determined to understand in detail how Twist mediates metastasis. To that end, she began by stably over-expressing Twist (MCF10ATw, 10ATw) in a human breast epithelial cell line (MCF10A, 10A) to study its function. Twist over-expression resulted in distinctive morphological changes in 10A cells, converting them from stereotypic epithelial to a disseminated structure with membrane protrusions. Migration and invasion assays confirmed that 10ATw cells were highly motile and invasive. This was in line with expectations.
 
However, when we further examined the mechanism of the changes, we found that the morphology that 10ATw cells displayed was dependent on the presence of epidermal growth factor (EGF), which was used to supplement the culture medium. When EGF was withdrawn from the medium, 10ATw cells lost their motile/invasive morphology and acquired a 10A-like phenotype. Moreover, no detectable migration was seen when EGF was absent. To dissect the molecular basis of this phenomenon, we performed quantitative PCR and found a 2.2-fold increase of EGF receptors (EGFR) in 10ATw cells compared to 10A cells. In addition, inhibition of MEK kinase with the EGF inhibitor U0126 led to an epithelial-like phenotype, similar to that of 10ATw cells cultured in the absence of EGF. However, no morphologic changes were observed in the MCF-10ATw cells with the addition of a PI3K inhibitor, LY294002.
 
Shan’s results therefore suggest that the EGFR/MEK/ERK signaling pathway mediates the Twist-induced changes in 10ATw cells. By demonstrating the correlation between Twist and EGFR, we show that Twist can not only change the physical connection between cells, but also alter cellular responses to the extracellular environment. When placed in a microenvironment coupled with activated EGFR ligands, Twist over-expressing cells can become more motile and invasive, which allows them to disseminate from the original tumor bed and metastasize to other sites in the body. Her manuscript, titled “Human breast stem cell transformation and invasiveness is mediated by upregulation of IL-8 by TWIST interaction with NF-kB,” is in progress.
 
Because Twist increases the invasiveness of breast tumor cells, we hope to introduce proteins that can interfere with Twist by blocking the affected cytokine signaling pathways to restore normal cellular activity. The function of cytokines in breast tumorigenesis has been well described and provides a molecular framework in which to devise novel anti-Twist therapies for highly invasive breast cancer.
 
Soluble Twist Inhibitors (STIs): A Novel Targeted Molecular Therapy in Metastatic Disease
Our laboratory aims to develop a series of soluble Twist inhibitors (STIs) and selectively deliver them (using neural stem cells, as described below) to metastatic breast cancer cells.  Therapeutic efficacy in a murine model will be assessed. This data will be used to refine drug development and eventually ready suitable candidates for human trials.
 
Raquel Raices, a postdoctoral fellow who joined our laboratory in August 2008, has commenced research in this area. We are currently seeking funding to proceed with this important and exciting project. Our objective is to design soluble Twist inhibitors (STIs). These are non-functional, dominant-negative Twist mutants that:
 
  • Inhibit activity of wild-type Twist
  • Reduce Twist-mediated migration/invasion of breast cancer cell lines in vitro
  • Prevent metastasis in a murine invasive breast cancer model
Raquel  has engineered three non-functional STIs (S144K/R145E, ∆183-202, and S144K/R145E/∆183-202) that act as dominant negatives of endogenous Twist function, as suggested by their lack of transcriptional activity as well as decreased activity of wild-type Twist on the IL-8 promoter (a Twist target) when co-expressed with STIs. STIs were fused to the N- and C-termini of the protein transduction domain, VP22, to facilitate transfer into the nucleus of target cells. VP22:STI fused genes are under the T7 promoter to facilitate expression in E. coli, and were tagged with 6XHis and c-myc  to facilitate purification and detection of recombinant protein.
 
For her experimental strategy, Raquel will perform an ex vivo incubation of recombinant VP22:STIs with the highly invasive SUM1315 breast cancer human cell line (VP22-fused recombinant proteins are taken up by target cells within 20 minutes). STI-mediated inhibition of endogenous Twist function in target SUM1315 cells will be assessed by Western blotting of EMT markers and migration/invasion assays. These results will be compared to those from SUM1315 cells treated with anti-Twist siRNA.
 
Neural stem cells (NSCs) possess the inherent ability to specifically migrate to primary and metastatic tumor sites. Because of this property, fetal HB1.F3.CD (a NSC cell line) will be transduced with AdVP22:STIs and used to deliver STIs to breast tumors and metastatic sites. The ability of transduced HB1.F3.CD cells to migrate towards SUM1315 will be evaluated in vitro using migration/invasion assays. Once HB1.F3.CD cells have migrated towards the cancer cells, expression of STIs will be induced by addition of doxycycline. VP22:STI should be released from NSCs and taken up by target cancer cells. The effect of STIs on SUM1315 expression of EMT markers will be assessed by Western blotting. Subsequently, SUM1315 cells will be genetically modified to express the firefly luciferase gene and used to establish a xenograft metastatic breast cancer model in nude mice. Tumor progression and metastasis will be assessed using a xenogen in vivo imaging system. Once NSC biodistribution is determined, transgene expression will be turned “on” with intravenous doxycycline administration only when NSCs have arrived to tumor sites, thereby avoiding complications of systemic delivery and minimizing any potential effect of loss of Twist function on NSC migration.
 
Given the role of Twist as a master regulator of breast cancer metastasis, NSC-mediated STI delivery to tumor sites represents a promising therapeutic strategy (combined with surgery or radiation to remove primary tumors) to reduce mortality due to breast cancer metastasis. Shan Li’s Ph.D. thesis project is evaluating the STIs for their capacity to selectively induce apoptosis and/or transformation of metastatic mammary cells to a normal differentiated or apoptotic phenotype.
 
Neural Stem Cells as Targeted Drug Delivery Vehicles
Capitalizing on the inherent migratory and tumor targeting abilities of human neural stem cells (NSCs) provides our rationale for developing sophisticated novel therapeutic modalities for the treatment of invasive neoplastic disease. In collaboration with Karen Aboody, our laboratory is investigating NSC-mediated delivery of three therapeutics for the treatment of metastatic breast cancer.
 
We therefore propose to use genetically engineered NSCs as a delivery vehicle to secrete:
 
  • Rabbit carboxylesterase (rCE), followed by systemic administration of CPT-11 [pro-drug therapy] Note: Donghong Zhou is the lead postdoctoral fellow on this project; she has just received a DoD concept award to pursue this innovative project.
  • anti-Her2/neu immunoglobulin [immunotherapy] Note: Rik Frank, a third-year student in the Aboody laboratory, has successfully cloned the full-length Her2/neu IgG in hNSCs and is testing its ability of the hNSCs to secrete Her2/neu in vitro and is evaluating its function using chemotoxicity assays. His first manuscript, “Stem cell-mediated targeted HER2 immunotherapy,” is in the process of being submitted.
  • Soluble TWIST inhibitors (STIs) [Transcription Factor (TF) targeted therapy] STIs are delivered to tumor sites to inhibit tumor growth and formation of metastases. We hypothesize that NSCs can effectively deliver these therapeutic agents selectively to breast tumor cells and significantly improve therapeutic efficacy in metastatic breast cancer mouse models.
 
Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 
NEWS & UPDATES
  • Counter-intuitive though it might seem, a prostate cancer diagnosis shouldn’t always lead to immediate prostate cancer treatment. Although prostate cancer is the second-leading cancer killer of men, behind lung cancer, and causes more than 29,000 deaths in the U.S. each year, in many cases, the tumors are...
  • Radiology is one of the cornerstones of any hospital. It is a key diagnostic branch of medicine essential for the initial diagnosis of many diseases and has an important role in monitoring a patient’s treatment and predicting outcome. Radiology is the specialty considered to be both the “eyes” and “ears” of med...
  • Donating blood and platelets saves lives. We all know this. Yet every summer, potential blood donors become distracted by vacations and schedule changes. As a result, blood donations fall dramatically across the nation, leaving hospitals frantically trying to bring in much-needed blood for their patients. Earli...
  • To be a great cancer hospital, you need a great oncology program. Just ask City of Hope – and Becker’s Hospital Review. The health care publishing industry stalwart, described as the “leading hospital magazine for hospital business news and analysis for hospital and health system executives,” recently selected ...
  • Diagnostic errors are far from uncommon. In fact, a recent study found that they affect about 12 million people, or 1 in 20 patients,  in the U.S. each year. With cancer, those errors in diagnosis can have a profound impact. A missed or delayed diagnosis can make the disease that much harder to treat, as the Ag...
  • Eleven years ago, lymphoma patient Christine Pechera began the long road toward a cancer-free life. She had been diagnosed with non-Hodgkin lymphoma and told by doctors elsewhere that her lifespan likely would be measured in months, not years. Refusing to give up, she came to City of Hope for a second opinion. ...
  • Brain surgery is not for the faint of heart. It takes courage, as well as curiosity and compassion. The truly great surgeons also have a desire to find new, and better ways, of healing the brain. Enter Behnam Badie, M.D., chief of neurosurgery at City of Hope. Now a pioneer in brain tumor treatment, Badie enter...
  • Elizabeth Budde, M.D., Ph.D., wants to encourage infighting. She aims to turn the immune system on itself — to the benefit of patients with acute myeloid leukemia, or AML. AML arises when abnormal white blood cells grow out of control, amassing in the bone marrow and interfering with normal blood cell developme...
  • Six, to date; more soon. Outpatient bone marrow transplants, that is. Finding new ways to deliver quality care with the greatest benefit is a priority for a patient-centered institution like City of Hope. For example, not every bone marrow transplant patient needs to check into the hospital for treatment. In fa...
  • The best measure of success in the fight against cancer is in lives saved and families intact, in extra days made special simply because they exist. Yuman Fong, M.D., chair of the Department of Surgery at City of Hope, understands what precedes that special awareness. When cancer strikes, one minute a person ma...
  • In cancer, expertise matters. So do survival rates, patient safety, patient services and many other factors. City of Hope understands this, as does U.S.News & World Report. The magazine’s 2014-2015 list of best hospitals for cancer once again includes City of Hope, ranking the institution 12 out of 900 elig...
  • At 29, Kommah McDowell was a successful young professional engaged to be married to her best friend. She worked in the financial services sector and kick-boxed to keep in shape and to relax. Then came the diagnosis of triple-negative inflammatory breast cancer, a rare and very aggressive form of breast cancer. ...
  • The well-known drug tamoxifen might not always be the best choice for premenopausal women who have undergone treatment for breast cancer and face a heightened risk of recurrence. A new study suggests that the aromatase inhibitor exemestane, or Aromasin, works slightly better than tamoxifen in preventing cancer ...
  • At age 44, Bridget Hanchette, a mother of three from La Crosse, Wisconsin, was diagnosed with grade IV glioblastoma, the most aggressive type of malignant brain tumor. The cancer grows and spreads quickly, making it difficult to treat. Most patients with this diagnosis are not given much hope, but Hanchette’s i...
  • Survival rates for childhood cancer have improved tremendously over the past few decades, but postcancer care hasn’t always kept up. More children than ever are now coping with long-term complications and side effects caused by their disease and treatment — one of those being learning difficulties. A new ...